DiaMedica Therapeutics Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount
DiaMedica Therapeutics Inc. (DMAC) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount of $137.00 thousand for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-23.
Discontinued
us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2020-03-23
- DiaMedica Therapeutics Inc. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2019 was $137.00K, a 33.01% increase from fiscal 2018.
- DiaMedica Therapeutics Inc. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2018 was $103.00K, a 67.20% decline from fiscal 2017.
- DiaMedica Therapeutics Inc. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2017 was $314.00K.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month |
|---|---|
| 2019-12-31 | $137.00K 10-K · filed 2020-03-23 |
| 2018-12-31 | $103.00K 10-K · filed 2020-03-23 |
| 2017-12-31 | $314.00K 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |